The effect on costs of the use of half-dose aprotinin for first-time reoperative coronary artery bypass patients

Clinical Therapeutics

Volumn 20, Issue 3, 1998, Pages 581-591

  Able, Mary E ^a   Tilly, Darcie A ^b  

^a John Muir Health   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aprotinin; Cost savings; Reoperative coronary artery bypass; Transfusion

Indexed keywords

APROTININ;

AGED; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE FINANCING; HEMOSTASIS; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE;

EID: 0031926007     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80067-2     Document Type: Article

References (16)

1. Bracey AW, Radovancevic R. Radovancevic B, et al. Blood use in patients undergoing repeat coronary artery bypass graft procedures: Multivariate analysis. Transfusion. 1995;35:850-854.
2. Royston D, Taylor KM, Bidstrup BP, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open heart surgery. Lancet. 1987;2:1289-1291.
3. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 1989;97:364-372.
4. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled study. Ann Thorac Surg. 1992; 54:1031-1038.
5. Bidstrup B, Underwood SR, Sapsford RN. Effect of aprotinin (Trasylol) on aortacoronary bypass graft patency. J Thorac Cardiovasc Surg. 1993;105:147-153.
6. Lemmer J, Stanford W, Bonney S, et al. Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg. 1994;107:543-553.
7. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 1994;107:554-561.
8. Bidstrup BP, Harrison J, Royston D, et al. Aprotinin therapy in cardiac operations: A report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg. 1993; 55:971-976.
9. Lemmer JH, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass grafting: Effect on postoperative renal function. Ann Thorac Surg. 1995;59: 132-136.
10. Harmon DE. Cost/benefit analysis of pharmacologic hemostasis. Ann Thorac Surg. 1996;61(Suppl 2):521-525, 533-534.
11. D'Errico CC, Shayevitz JR, Martindale SJ, et al. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg. 1996; 83:1193-1199.
12. Baele PL, Ruiz-Gomez J, Londot C, et al. Systematic use of aprotinin in cardiac surgery: Influence on total homologous exposure and hospital care. Acta Anaesthesiol Belg. 1992;43:103-112.
13. Edwards FH, Clark RE, Schwartz M. Coronary artery bypass grafting: The Society of Thoracic Surgeons National Database experience. Ann Thorac Surg. 1994; 57:12-19.
14. Wachtfogel YT, Hack CE, Nuijens JH, et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol. 1995;268(3 Part 2):H1352-H1357.
15. Nagaoka H, Yamacia T, Hatano R, et al. Clinical significance of bradykinin liberation during cardiopulmonary bypass and its prevention by a kallikrein inhibitor. Jpn J Surg. 1975;5:222-233.
16. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg. 1993;105:712-720.